GSK plc (GSK,GSK.L) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the expansion of the indication for its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, to include all adults aged 18 years and older.
A final decision from the European Commission is expected in February 2026. If approved, this expanded indication would make Arexvy available to all adults 18+, broadening access beyond the current approvals.
Arexvy was the first RSV vaccine approved in Europe for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older, as well as those aged 50-59 at increased risk of RSV disease.
RSV is a common contagious virus affecting the lungs and breathing passages and impacts an estimated 64 million people of all ages globally every year. RSV can exacerbate certain medical conditions, and lead to severe illness resulting in hospitalisation and even death.
GSK is continuing to seek expanded indications for its RSV vaccine in other geographies including the US and Japan.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.